United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

patientric ltd - salmonella typhi strain ty 21a - gastro-resistant capsule

New Zealand - English - Medsafe (Medicines Safety Authority)

biocelect new zealand ltd - salmonella typhi strain ty21a berna 2000 million organisms (minimum); salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum); salmonella typhi strain ty21a berna 2000 million organisms - modified release capsule - 2000 million organisms - active: salmonella typhi strain ty21a berna 2000 million organisms (minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate lactose fast flo iron oxide red iron oxide yellow lactose monohydrate magnesium stearate sucrose titanium dioxide active: salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate sucrose titanium dioxide active: salmonella typhi strain ty21a berna 2000 million organisms excipient: ascorbic acid diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate methanol methylene chloride protein hydrolysate sucrose titanium dioxide - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - salmonella typhimurium; thiomersal; aluminium hydroxide gel - parenteral liquid/solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 p; thiomersal mercury other 0.13 mg/ml; aluminium hydroxide gel mineral-aluminium-base other 0.0 p - immunotherapy - horse foal | horse mare (female) | female horse - salmonella typhimurium | vaccine | equine rotavirus

Australia - English - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - salmonella typhi -

Israel - English - Ministry of Health

kamada ltd, israel - viable salmonella typhi ty21a cells - gastro resistant hard capsule - viable salmonella typhi ty21a cells - vivotif is indicated for active oral immunisation against typhoid fever, caused by salmonella enterica serovar typhi, (s. typhi), in adults and children aged five years and older.this vaccine should be used in accordance with official recommendations

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - salmonella typhimurium - oral solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 undefined - immunotherapy - poultry chicks | turkey poult (young) | chickens | day old chicks | hatchlings | turkeys - day old poults | young turkey - salmonella enteridis | salmonella typhimurium | vaccine | equine rotavirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated salmonella dublin & typhimurium antigens; thiomersal - misc. vaccines or anti sera - inactivated salmonella dublin & typhimurium antigens vaccine-microbial active 0.0 undefined; thiomersal mercury other 0.1 mg/ml - immunotherapy - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - salmonella | including b-lactamase producin | salmonellosis

United States - English - NLM (National Library of Medicine)

rebel distributors corp - salmonella enterica subsp. enterica serovar typhi (unii: 760t5r8b3o) (salmonella enterica subsp. enterica serovar typhi - unii:760t5r8b3o) - salmonella enterica subsp. enterica serovar typhi 2 [cfu] - vivotif (typhoid vaccine live oral ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by salmonella typhi . routine typhoid vaccination is not recommended in the united states of america. selective immunization against typhoid fever is recommended for the following groups: 1) travelers to areas in which there is a recognized risk of exposure to s. typhi , 2) persons with intimate exposure (e.g. household contact) to a s. typhi carrier, and 3) microbiology laboratorians who work frequently with s. typhi (7). there is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps. not all recipients of vivotif will be fully protected against typhoid fever. vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. the vaccine will not afford protection against species of salmonella other than salmonella

United States - English - NLM (National Library of Medicine)

apotheca company - salmonella enterica subsp. enterica serovar enteritidis (unii: y3v16d4pv4) (salmonella enterica subsp. enterica serovar enteritidis - unii:y3v16d4pv4) - salmonella enterica subsp. enterica serovar enteritidis 30 [hp_x] in 1 ml - indications:   to be used according to standard homeopathic indications. indications: to be used according to standard homeopathic indications.

Australia - English - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - salmonella typhi, quantity: 2000 million organisms - capsule, enteric - excipient ingredients: sucrose; ascorbic acid; protein hydrolysate; ethylene glycol; lactose; hypromellose phthalate; erythrosine; iron oxide red; titanium dioxide; magnesium stearate; diethyl phthalate; gelatin; iron oxide yellow - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.